immunolog
assay
detect
antibodi
sarscov
develop
inhous
avail
commerci
howev
antigen
use
assay
differ
order
valid
reliabl
assay
standard
panel
establish
studi
express
purifi
sever
acut
respiratori
syndrom
sar
structur
protein
fragment
develop
indirect
enzymelink
immunosorb
assay
elisa
detect
antibodi
sar
n
n
n
c
protein
well
human
coronaviru
n
protein
assay
use
screen
sampl
sar
convalesc
patient
serial
serum
specimen
patient
differ
phase
sar
infect
plasma
specimen
normal
blood
donor
sampl
normal
blood
donor
also
test
antibodi
respiratori
viru
repres
sampl
chosen
compris
refer
panel
sar
antibodi
may
use
detect
sar
panel
compos
posit
sampl
neg
sampl
dilut
sampl
antin
antibodi
dilut
sampl
anti
antibodi
one
sampl
valid
precis
comparison
detect
result
differ
sar
antibodi
assay
indic
panel
differenti
specif
sensit
differ
assay
coronavirus
import
pathogen
mostli
caus
respiratori
enter
diseas
sever
acut
respiratori
syndrom
coronaviru
sarscov
newli
identifi
human
coronaviru
differ
previous
known
human
coronavirus
approxim
kb
genom
largest
among
rna
virus
encod
nonstructur
structur
protein
structur
protein
includ
spike
nucleocapsid
n
membran
small
envelop
e
protein
protein
larg
membran
protein
induc
neutral
antibodi
n
protein
thought
particip
replic
transcript
viral
rna
also
highli
immunogen
induc
strong
antibodi
respons
transmembran
protein
abund
glycoprotein
e
protein
integr
membran
protein
viral
envelop
embed
e
protein
surround
helic
nucleocapsid
consist
viral
rna
n
protein
immunogen
induc
immun
respons
infect
outbreak
sar
sever
differ
assay
laboratori
diagnosi
sar
develop
assay
includ
revers
transcriptasepolymeras
chain
reaction
rtpcr
detect
nucleic
acid
well
immunolog
assay
detect
n
antigen
antibodi
sarscov
protein
diagnost
techniqu
chosen
base
time
avail
equip
expertis
biolog
natur
avail
sampl
although
detect
n
antigen
rna
use
earli
diagnosi
sarscov
infect
antibodi
detect
wide
use
diagnost
epidemiolog
purpos
therefor
immunolog
assay
detect
antibodi
develop
inhous
avail
commerci
howev
antigen
use
assay
differ
use
inactiv
whole
viru
other
use
recombin
polypeptid
even
synthes
peptid
antibodi
differ
viral
protein
even
antigen
fragment
may
induc
present
signific
antibodi
diagnosi
cours
prognosi
sar
absolut
clear
kinet
antibodi
respons
correl
presenc
singl
antibodi
antibodi
entir
viru
also
unknown
valid
reliabl
assay
made
differ
antigen
standard
panel
need
establish
studi
sar
n
protein
fragment
express
purifi
sampl
convalesc
sar
patient
blood
donor
screen
enzymelink
immunosorb
assay
elisa
develop
protein
proper
sampl
select
compris
refer
panel
sarscov
antibodi
plasma
specimen
collect
patient
clinic
diagnos
sarscov
infect
recov
least
month
beij
guangdong
shanxi
provinc
specimen
incub
c
one
hour
inactiv
viru
store
c
serial
serum
specimen
collect
patient
clinic
diagnos
sar
day
infect
sampl
store
c
detect
carri
laboratori
plasma
specimen
n
unsuit
transfus
collect
beij
blood
center
influenza
igg
influenza
b
igg
mycoplasma
penumonia
igg
parainfluenza
igg
adenoviru
igg
respiratori
syncyti
viru
igg
measl
igg
mump
igg
elisa
manufactur
iblhamburg
gmbh
hamburg
germani
elisa
kit
detect
antisarscov
igg
antibodi
manufactur
euroimmun
medizinisch
labordiagnostika
ag
germani
gbi
biotechnolog
compani
beij
china
elisa
kit
detect
sarscov
n
protein
rtpcr
kit
detect
sar
cov
rna
manufactur
haitai
biopharmaceut
compani
zhuhai
china
daan
gene
compani
shenzhen
china
respect
domest
kit
use
studi
accredit
licens
state
food
drug
administr
sfda
china
kit
use
accord
manufactur
instruct
cdna
sarscov
structur
protein
n
clone
sar
patient
guangdong
provinc
store
laboratori
protein
purchas
biodesign
intern
saco
main
usa
express
recombin
plasmid
human
coronaviru
hcov
n
protein
gift
professor
che
xiaoyan
zhujiang
hospit
guangzhou
n
gene
divid
two
fragment
n
w
n
w
overlap
gene
divid
three
fragment
w
c
w
w
also
overlap
one
anoth
moreov
amino
acid
close
n
terminu
amino
acid
close
c
terminu
protein
predict
signal
peptid
transmembran
region
respect
remov
primer
n
n
n
c
gene
fragment
sarscov
design
accord
sequenc
sarscov
urbani
strain
bamhi
ndei
site
ad
terminu
forward
revers
primer
respect
use
ml
cdna
templat
pcr
carri
ml
reaction
pmol
primer
u
taq
polymeras
reaction
mix
inactiv
c
min
follow
cycl
c
c
c
final
extens
c
min
primer
pair
n
forward
n
revers
amplifi
n
bp
n
forward
n
revers
amplifi
n
bp
n
forward
n
revers
amplifi
n
bp
forward
revers
amplifi
bp
c
forward
c
revers
amplifi
c
bp
forward
revers
amplifi
bp
shown
restrict
site
ital
pcr
product
digest
bamhi
ndei
ligat
transform
e
coli
posit
plasmid
identifi
transform
express
strain
e
coli
bacteria
incub
c
shake
od
reach
isopropylbdthiogalactopyranosid
iptg
final
concentr
mmoll
ad
bacteria
incub
c
shake
h
recombin
plasmid
carri
n
gene
hcov
hcov
respect
express
similarli
e
coli
express
level
protein
analyz
use
gel
scan
softwar
alphaeasefc
sinc
sar
n
n
n
protein
n
protein
hcov
hcov
express
solubl
form
e
coli
bacteria
harvest
express
lyse
sonic
resuspend
differ
buffer
accord
purif
method
sinc
sar
c
protein
express
inclus
bodi
host
bacteria
harvest
express
lyse
sonic
wash
twice
dissolv
urea
sar
n
protein
lysat
ad
anionexchang
chromatographi
column
second
elut
peak
moll
nacl
collect
buffer
exchang
protein
ad
hydrophob
interact
chromatographi
column
second
elut
peak
moll
nh
collect
obtain
pure
sar
n
protein
sar
n
c
hcov
n
protein
lysat
ad
ni
chelat
affin
column
protein
elut
mmoll
mmoll
mmoll
imidazol
purifi
protein
obtain
fraction
elut
mmoll
imidazol
sar
n
protein
lysat
appli
sodium
dodecyl
sulfat
sd
gel
put
chamber
gel
elut
elut
min
solut
hole
collect
determin
pure
sdspolyacrylamid
gel
electrophoresi
sdspage
hcov
n
protein
lysat
ad
ni
chelat
affin
chromatographi
column
peak
elut
mmoll
imidazol
collect
protein
appli
sdspage
gel
elut
use
gel
elut
describ
determin
pure
sdspage
express
level
protein
analyz
use
gel
scan
softwar
alphaeasefc
western
blot
analysi
perform
determin
antigen
antigen
purifi
protein
separ
use
sdspage
subsequ
transfer
nitrocellulos
membran
nitrocellulos
membran
block
skim
milk
overnight
room
temperatur
incub
h
sarscov
antibodi
posit
human
serum
dilut
room
temperatur
wash
five
time
phosphatebuff
salin
pbst
membran
incub
h
alkalin
phosphataselabel
goat
antihuman
igg
dilut
room
temperatur
membran
wash
five
time
pbst
transfer
nbtbcip
solut
incub
room
temperatur
signal
observ
microtit
plate
coat
purifi
recombin
protein
phosphat
buffer
ph
h
follow
c
h
coat
plate
incub
c
overnight
wash
five
time
block
skim
milk
pbst
overnight
room
temperatur
wash
five
time
plasma
sera
specimen
ad
well
dilut
incub
c
h
well
wash
time
incub
peroxidaselabel
goat
antihuman
antibodi
c
min
wash
time
peroxidas
reaction
visual
use
tmb
substrat
min
c
dark
reaction
stop
ad
mlwell
n
h
absorb
read
nm
determin
cutoff
valu
specimen
normal
blood
donor
test
elisa
mean
od
standard
deviat
calcul
cutoff
valu
defin
mean
od
plu
three
standard
deviat
elisa
target
gene
fragment
n
n
n
c
sarscov
amplifi
cdna
size
expect
posit
recombin
plasmid
express
fragment
identifi
design
petsar
n
petsar
n
petsar
n
petsar
petsar
c
petsar
respect
express
product
recombin
plasmid
analyz
use
sdspage
gel
fig
n
n
n
recombin
polypeptid
sarscov
express
solubl
form
expect
size
kd
respect
c
polypeptid
found
inclus
bodi
size
kd
respect
recombin
plasmid
carri
n
gene
hcov
hcov
express
e
coli
n
protein
could
express
solubl
form
fig
percentag
sar
n
n
n
c
protein
express
total
protein
respect
hcov
hcov
total
protein
express
product
success
purifi
use
variou
purif
method
analyz
sdspage
gel
fig
purif
detail
see
section
puriti
sar
n
n
n
c
protein
respect
puriti
hcov
hcov
protein
test
reactiv
sar
recombin
protein
western
blot
analysi
carri
use
sarscovposit
human
serum
six
specif
band
correspond
molecular
weight
sar
n
n
n
c
protein
observ
fig
confirm
authent
recombin
protein
indirect
elisa
kit
detect
antibodi
differ
polypeptid
develop
use
correspond
polypeptid
base
reactiv
serum
uninfect
individu
od
cutoff
valu
sarscov
n
n
n
c
protein
hcov
n
protein
respect
among
sar
convalesc
plasma
specimen
percentag
igg
antibodi
sarscov
n
n
n
c
protein
respect
tabl
show
differ
antigen
sarscov
polypeptid
sar
convalesc
plasma
igg
immunoglobulin
detect
n
protein
hcov
indic
crossreact
occur
n
protein
sarscov
hcov
igg
igm
immunoglobulin
detect
sar
convalesc
plasma
specimen
use
indirect
elisa
develop
entir
viru
antigen
preval
igg
immunoglobulin
igm
immunoglobulin
sar
n
protein
protein
shown
low
antigen
n
n
c
protein
better
antigen
therefor
igg
immunoglobulin
n
n
c
protein
detect
indirect
elisa
sar
serial
sera
taken
day
onset
clinic
diagnos
diseas
result
show
earli
phase
infect
detect
rate
antibodi
sarscov
protein
high
detect
rate
n
protein
low
howev
detect
rate
appear
increas
later
phase
infect
fig
twentyf
plasma
specimen
sar
convalesc
patient
show
reactiv
sar
structur
protein
select
posit
refer
posit
antibodi
sar
whole
viru
neg
antibodi
hcov
n
protein
among
posit
antibodi
entir
n
n
n
c
protein
respect
sampl
show
strong
reactiv
n
fragment
other
show
strong
reactiv
fragment
shown
tabl
sampl
tabl
react
strongli
protein
sampl
react
strongli
n
protein
therefor
valid
sensit
elisa
detect
n
protein
serial
dilut
defibr
plasma
use
sensit
sampl
dilut
sampl
n
protein
design
dilut
dilut
respect
dilut
sampl
also
test
antibodi
n
n
c
recombin
protein
well
whole
viru
result
list
tabl
confirm
dilut
sn
sampl
react
strongli
n
fragment
protein
dilut
ss
sampl
react
strongli
fragment
protein
sampl
tabl
dilut
time
defibr
plasma
use
refer
coeffici
variat
valid
precis
diagnosi
reagent
posit
sampl
sensit
sampl
cv
sampl
detect
sar
cov
rna
n
antigen
accredit
kit
result
indic
none
posit
sar
cov
rna
n
antigen
sampl
includ
neg
sampl
posit
sampl
dilut
sampl
strong
posit
reactiv
antin
antibodi
dilut
sampl
strong
posit
reactiv
anti
antibodi
sampl
ml
per
vial
one
sampl
valid
coeffici
variat
ml
per
vial
aliquot
total
set
refer
panel
establish
aliquot
panel
valid
three
differ
sar
antibodi
assay
result
indic
differ
assay
differ
capac
detect
posit
sampl
dilut
sampl
tabl
sar
spread
quickli
broken
almost
countri
sinc
first
found
guangdong
provinc
china
novemb
becam
new
sever
infecti
diseas
centuri
threaten
health
peopl
world
present
signific
antibodi
diagnosi
cours
prognosi
sar
unclear
well
kinet
antibodi
respons
note
sampl
consid
posit
sco
valu
equal
correl
presenc
antibodi
singl
protein
antibodi
entir
viru
studi
indirect
elisa
develop
differ
fragment
sar
structur
protein
use
detect
antibodi
sar
plasma
specimen
donat
convalesc
patient
month
onset
sar
result
indic
express
protein
react
convalesc
plasma
surpris
sar
n
protein
exhibit
low
antigen
activ
activ
n
n
protein
fragment
whole
n
protein
better
follow
reason
explain
phenomenon
firstli
describ
section
sar
n
protein
purifi
complic
polystep
purif
method
may
result
chang
n
protein
structur
properti
next
sinc
express
e
coli
perhap
sar
whole
n
protein
could
form
natur
structur
antigen
conform
epitop
may
expos
protein
fragment
moreov
entir
sar
n
protein
react
part
neg
sampl
reveal
may
crossreact
sar
nonsar
plasma
result
report
mimoun
etc
probabl
antigen
epitop
similar
conserv
n
protein
human
tissu
antigen
undetect
pathogen
meanwhil
antigen
sar
protein
poor
base
bioinfomat
analysi
protein
globular
domain
protein
conform
globular
protein
usual
complic
antigen
epitop
may
compos
mani
polypeptid
far
away
one
anoth
linear
sequenc
fold
modifi
function
prokaryot
express
system
reduct
antigen
activ
perhap
conform
protein
replic
prokaryot
express
system
indirect
elisa
kit
igg
igm
appli
detect
antibodi
plasma
specimen
result
consist
studi
detect
rate
antibodi
sarscov
protein
sar
serial
serum
specimen
high
earli
phase
infect
suggest
detect
protein
could
help
earli
diagnosi
although
detect
rate
n
protein
low
earli
stage
diseas
appear
increas
later
stage
sinc
virus
replic
larg
scale
infect
human
immun
initi
substanti
declin
antibodi
detect
rate
rise
immun
recov
treatment
sinc
coronavirus
ubiquit
infect
hcov
hcov
common
crossreact
hcov
sarscov
increas
rate
misdiagnosi
therefor
develop
indirect
elisa
kit
detect
igg
n
protein
hcov
hcov
test
sar
plasma
specimen
result
show
crossreact
howev
crossreact
n
protein
hcov
sarscov
observ
studi
probabl
sampl
suffici
examin
crossreact
studi
preval
antibodi
influenza
viru
influenza
b
viru
mycoplasma
pneumonia
parainfluenza
viru
adenoviru
respiratori
syncyti
viru
measl
viru
mump
viru
also
analyz
among
normal
blood
donor
result
indic
preval
antibodi
mycoplasma
pneumonia
preval
antibodi
influenza
viru
respiratori
syncyti
viru
studi
sampl
posit
sarscov
antibodi
sampl
posit
respiratori
viru
antibodi
neg
sarscov
antibodi
dilut
sampl
strong
antibodi
protein
dilut
sampl
strong
antibodi
n
protein
one
sampl
valid
coeffici
variat
valid
precis
select
compris
refer
panel
sarscov
antibodi
posit
sampl
collect
guangdong
shanxi
beij
titer
antibodi
differ
strongli
posit
weak
other
middl
posit
sampl
neg
sar
cov
rna
n
antigen
neg
sampl
mainli
select
sampl
posit
antibodi
respiratori
virus
crossreact
virus
specif
may
valid
found
sampl
stronger
antibodi
n
protein
stronger
antibodi
protein
although
signific
antibodi
n
protein
clear
diagnost
purpos
assay
sensit
valid
therefor
sensit
sampl
antin
anti
antibodi
includ
refer
panel
studi
set
panel
gener
volum
ml
vial
fact
sar
cov
antibodi
assay
use
indirect
sandwich
method
approxim
ml
sampl
would
use
run
meanwhil
ml
plasma
left
sampl
panel
store
c
aliquot
case
emerg
therefor
panel
suffici
use
valid
sar
antibodi
assay
candid
sampl
differ
background
select
compris
refer
panel
valid
differ
sar
antibodi
assay
result
show
differ
assay
differ
capac
detect
posit
sampl
panel
use
valid
sensit
specif
sarscov
antibodi
assay
make
assay
reliabl
